Morel, O <br/><br/>
Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists.  [electronic resource] 

 -  Journal of thrombosis and haemostasis : JTH  Jul 2004 
 - 1118-26 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1538-7933 
<br/><br/><label>Standard No.: </label>10.1111/j.1538-7836.2004.00805.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Adrenergic beta-Antagonists--therapeutic use<br/>Adult<br/>Aged<br/>Angioplasty, Balloon, Coronary--adverse effects<br/>Antibodies, Monoclonal--pharmacology<br/>Aspirin--therapeutic use<br/>Biomarkers--blood<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoglobulin Fab Fragments--pharmacology<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--blood<br/>Particle Size<br/>Platelet Aggregation Inhibitors--pharmacology<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Platelet Glycoprotein GPIb-IX Complex--analysis<br/>Predictive Value of Tests<br/>Prognosis<br/>Solubility<br/>Thrombophilia--diagnosis